Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437505 | 0.92 | SMN1; SMN2 (0.43) | CYP11B1CYP11B2CYP1A2CYP17A1MAPT | |
| SCHEMBL4448983 | 0.90 | CYP11B1 (0.41) | CYP11B1CYP11B2CYP1A2CYP17A1MAPT | |
| SCHEMBL19051717 | 0.83 | CYP17A1 (0.45) | CYP11B1CYP11B2CYP1A2CYP17A1MAPT | |
| SCHEMBL2007798 | 0.82 | CCR1 (0.41) | CYP11B1CYP11B2CYP1A2CYP17A1MAPT | |
| SCHEMBL2008964 | 0.82 | CYP11B1 (0.45) | CYP11B1CYP11B2CYP1A2CYP17A1HSD17B1 | |
| SCHEMBL2006806 | 0.80 | NR3C1 (0.42) | CYP11B1CYP11B2CYP1A2CYP17A1CYP3A4 | |
| SCHEMBL27799392 | 0.78 | CYP1A2 (0.51) | CYP11B1CYP11B2CYP1A2CYP17A1MAPT | |
| SCHEMBL4113695 | 0.77 | CYP17A1 (0.54) | CYP11B1CYP11B2CYP1A2CYP17A1NR3C1 | |
| SCHEMBL2006080 | 0.75 | CYP11B2 (0.46) | CYP11B1CYP11B2CYP1A2CYP17A1NPC1 | |
| SCHEMBL16910734 | 0.74 | TP53 (0.41) | CYP1A2MAPTSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | claimed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| CN-101679288-A | Indazoles for treating estrogen receptor beta mediated diseases | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | claimed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| CN-101679288-A | Indazoles for treating estrogen receptor beta mediated diseases | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2118068-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008107455-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107455-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GPER1, ESR2, ESRRB | CYP11B1 20/4885CYP11B2 14/4885CYP1A2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.